← back to search

Jaime Feliú

Medical Research Network · ES
🔎 Find collaborators in Oncology · Pulmonary and Respiratory Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes, and Genetic factors in colorectal cancer.
h-index
44
citations
7,277
works
458
NIH funding
primary concept
Medicine
email

Recent publications

An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.
2025cited by 12position: contributordoi
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.
2025cited by 7position: contributordoi
Miraculin Can Contribute to a Reduction in Inflammatory Biomarkers and Cachexia in Malnourished Patients with Cancer and Taste Disorders.
2025cited by 2position: contributordoi
Effect of a Novel Food Rich in Miraculin on the Intestinal Microbiome of Malnourished Patients with Cancer and Dysgeusia.
2025cited by 2position: contributordoi
Data from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
2025cited by 1position: contributordoi
Supplementary Table S1 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
2025cited by 0position: contributordoi
Supplementary Table S3 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
2025cited by 0position: contributordoi
Supplementary Data 2 from An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025cited by 0position: contributordoi
Supplementary Table S5 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
2025cited by 0position: contributordoi
Data from An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025cited by 0position: contributordoi
Supplementary Table S2 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
2025cited by 0position: contributordoi
Supplementary Table S4 from A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
2025cited by 0position: contributordoi
Supplementary Data 1 from An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025cited by 0position: contributordoi
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
Clinical Cancer Research 2024cited by 11position: middledoi
Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study.
2024cited by 7position: contributordoi
Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer?
2024cited by 2position: contributordoi
The Regular Consumption of a Food Supplement Containing Miraculin Can Contribute to Reducing Biomarkers of Inflammation and Cachexia in Malnourished Patients with Cancer and Taste Disorders: The CLINMIR Pilot Study
2024cited by 2position: contributordoi
Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia.
2024cited by 2position: contributordoi
Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis.
2024cited by 1position: contributordoi
Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: the CLINMIR Pilot Study
2024cited by 0position: contributordoi
Layer Analysis Based on RNA-Seq Reveals Molecular Complexity of Gastric Cancer.
2024cited by 0position: contributordoi
Effect of a novel food rich in miraculin on the intestinal microbiome of malnourished patients with cancer and dysgeusia
2024cited by 0position: contributordoi
Effect of Regular Consumption of a Miraculin-Based Food Supplement on Taste Perception and Nutritional Status in Malnourished Cancer Patients: A Triple-Blind, Randomized, Placebo-Controlled Clinical Trial-CLINMIR Pilot Protocol.
2023cited by 10position: contributordoi
The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic Adenocarcinoma.
2023cited by 6position: contributordoi
Clinico-Pathological Features, Outcomes and Impacts of COVID-19 Pandemic on Patients with Early-Onset Colorectal Cancer: A Single-Institution Experience.
2023cited by 6position: contributordoi
Predicting Risk of Severe Toxicity and Early Death in Older Adult Patients Treated with Chemotherapy.
2023cited by 3position: contributordoi
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma.
2023cited by 3position: contributordoi
Effect of Regular Consumption of a Miraculin-Based Food Supplement on Taste Perception and Nutritional Status in Malnourished Cancer Patients: A Triple-Blind, Randomized, Placebo-Controlled Clinical Trial. CLINMIR Pilot Protocol
2023cited by 0position: contributordoi
Supplementary Table 3 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
2023cited by 0position: contributordoi
Supplementary Figure 1 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 57 papers (2020–2025) · 26 papers (2021–2025)Bruno Bockorny · Boston Medical Center26 papers (2021–2025)Ravit Geva · Tel Aviv University20 papers (2021–2023) · 19 papers (2021–2023)Paul E. Oberstein · Hematology Oncology Associates19 papers (2021–2023) · 19 papers (2021–2023)Mariano Ponz-Sarvise · Centro de Investigación Biomédica en Red de Cáncer19 papers (2021–2023) · 19 papers (2021–2023) · 19 papers (2021–2023)Bricia López-Plaza · Universidad Complutense de Madrid9 papers (2023–2025)Ángel Gil · Centro de Investigación Biomédica en Red de Enfermedades Respiratorias8 papers (2023–2025)Rocio Garcia-Carbonero · Hôpital Saint-Antoine8 papers (2020–2025)Laura Medina · Hospital Clínico Universitario Virgen de la Victoria8 papers (2023–2025)Thomas Hummel · Klinik und Poliklinik für Augenheilkunde am Universitätsklinikum Carl Gustav Carus7 papers (2023–2025)Ignacio Juez · Hospital Universitario de Fuenlabrada7 papers (2025–2025)Senthil K. Muthuswamy · National Institutes of Health7 papers (2025–2025)Pedro P. Lopez-Casas · Hospital Universitario Virgen de la Arrixaca7 papers (2025–2025)Sofia Perea · 7 papers (2025–2025)Manuel Hidalgo · Artistic Realization Technologies7 papers (2025–2025)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Pulmonary and Respiratory Medicine →